Unlike previous research that has predominantly focused on the well-established association between SLCO1B1 and SAMS risk [4,5,6,7,8], this investigation specifically evaluated lipid-lowering effectiveness across different SLCO1B1 phenotypes. The gene discussed is SLCO1B1; the disease is short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.